Objectives. Determine the optimal, licensed, first-line anticoagulant for prevention of
ischemic stroke in patients with non-valvular atrial fibrillation (AF) in England and Wales …

Purpose Three new oral anticoagulants (NOACs) have recently become available in the
United Kingdom as an alternative to warfarin in the prevention of stroke and systemic …

Abstract Background Apixaban (5 mg BID), dabigatran (available as 150 mg and 110 mg
BID in Europe), and rivaroxaban (20 mg once daily) are 3 novel oral anticoagulants …

Objective To determine the cost-effectiveness of apixaban versus warfarin in patients with
atrial fibrillation (AF) with a moderate to severe risk of stroke, from an Australian government …

Purpose The purpose of this analysis was to assess the cost-effectiveness of apixaban 5 mg
BID versus high-and low-dose edoxaban (60 mg and 30 mg once daily) as intended starting …

Background: Warfarin has been used as the only oral anticoagulant for over 50 years in
patients with atrial fibrillation. Recently new oral anticoagulants like dabigatran, rivaroxaban …

Objective To determine the clinical and cost effectiveness of apixaban compared to aspirin
in the prevention of thromboembolic events for patients with atrial fibrillation for whom …

The concept of net clinical benefit has been used to quantify the balance between risk of
ischaemic stroke (IS) and risk of intracranial haemorrhage (ICH) with the use oral …

Abstract Background and Objective Management of non-valvular atrial fibrillation (NVAF)
focuses on the use of anticoagulation to mitigate the risk of stroke. Until recently, vitamin K …

Purpose Direct oral anticoagulant (DOAC) use for the prevention of thromboembolic
complications in patients with non-valvular atrial fibrillation (AF) has increased steadily in …